Figure 4: A comparison of fused FLT- and FDG-PET/CT scans and tumor Ki-67 immunohistochemistry for Patient 3 obtained before (pre-C225) and after (post-C225) induction cetuximab. FLT SUVmax, FDG SUVmax, and Ki- 67 proliferative index did not change significantly in response to induction therapy.